

Product Data Sheet

Product Name: (Pro³)-Gastric Inhibitory Polypeptide (human)

Cat. No.: GA20278

Chemical Properties

Cas. No. 299898-52-5

Formula C₂₂₆H₃₃₈N₆₀O₆₄S

M.Wt 4951.6

Solubility Soluble in DMSO

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Protocol

Cell experiment [1]:

Cell lines COS-7 cells (African green monkey kidney fibroblast-like cell line) transiently transfected with human GIP receptor cDNA

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Transfected COS-7 cells were assayed for cAMP accumulation. Cells were
Preparation Method stimulated with species-specific (Pro3)-Gastric Inhibitory Polypeptide (4.7nM to 92nM) at the indicated concentration range for 30 minutes.

Reaction
Conditions 4.7nM to 92nM; 30 minutes.

Applications (Pro3)-Gastric Inhibitory Polypeptide acted as a full agonist with similar efficacy as native human GIP at the human GIP receptor.

Animal experiment [2]:

Animal models Obese diabetic (ob/ob) mice

Mice were fasted for 18 hours, then intraperitoneally administered a single dose of (Pro3)-Gastric Inhibitory Polypeptide (25nmol/kg). Following injection, the
Preparation Method mice were allowed to re-feed for 15 minutes. Blood samples were collected at 0, 15, 30, 60, and 120 minutes post-injection for plasma insulin and glucose analysis.

Dosage form 25nmol/kg; i.p.; single injection.

Applications Administration of (Pro3)-Gastric Inhibitory Polypeptide significantly decreased the postprandial plasma insulin response in fasted mice, reducing the overall insulin release. (Pro3)-Gastric Inhibitory Polypeptide also lowered the basal hyperinsulinaemia in non-fasted mice. Accompanying changes in plasma glucose concentrations were minimal.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

- [1] Sparre-Ulrich AH, Hansen LS, Svendsen B, et al. Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. *Br J Pharmacol*. 2016 Jan;173(1):27-38.
- [2] Gault VA, O'Harte FP, Harriott P, et al. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. *Diabetologia*. 2003 Feb;46(2):222-30.

Background

(Pro3)-Gastric Inhibitory Polypeptide (human) is an analog of human glucose-dependent insulinotropic polypeptide (GIP), distinguished by the substitution of proline for glutamate at the third amino acid position. (Pro3)-Gastric Inhibitory Polypeptide acts as a potent, stable, and specific full agonist of the human GIP receptor (hGIPR), exhibiting high binding affinity ($K_i/K_d=0.90\text{nM}$)^[1-2]. (Pro3)-Gastric Inhibitory Polypeptide is used in research related to obesity-associated diabetes and type 2 diabetes^[3-4].

In vitro, using isolated human atrial preparations, simultaneous stimulation with (Pro3)-Gastric Inhibitory Polypeptide (100nM) and Tirzepatide (100nM) was performed. (Pro3)-Gastric Inhibitory Polypeptide attenuated the positive inotropic effect induced by Tirzepatide. (Pro3)-Gastric Inhibitory Polypeptide antagonized the GIP receptor-mediated enhancement of myocardial contractility^[5]. COS-7 cells transiently transfected with the human GIP receptor were stimulated with (Pro3)-Gastric Inhibitory Polypeptide (4.7nM to 92nM) for 30 minutes. (Pro3)-Gastric Inhibitory Polypeptide acted as a full agonist with similar efficacy to native human GIP at the human GIP receptor^[6].

In vivo, (Pro3)-Gastric Inhibitory Polypeptide (25nmol/kg) was administered via intraperitoneal injection once or twice daily to high-fat diet-induced obese diabetic mice for 48 days. (Pro3)-Gastric Inhibitory Polypeptide significantly improved glucose tolerance and insulin sensitivity, and reduced weight gain and hyperinsulinemia^[7]. In fasted obese diabetic (ob/ob) mice, a single intraperitoneal injection of (Pro3)-Gastric Inhibitory Polypeptide (25nmol/kg) was administered. (Pro3)-Gastric Inhibitory Polypeptide significantly reduced the plasma insulin response 15 minutes after re-feeding,

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

decreasing overall insulin release by 42%. In non-fasted ob/ob mice, a single intraperitoneal injection of (Pro3)-Gastric Inhibitory Polypeptide (25nmol/kg) ameliorated the basal hyperinsulinemia^[8].

References:

- [1] Rosenkilde MM, Lindquist P, Kizilkaya HS, et al. GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology. *Peptides*. 2024 Jul;177:171212.
- [2] McClean PL, Irwin N, Cassidy RS, et al. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. *Am J Physiol Endocrinol Metab*. 2007 Dec;293(6):E1746-55.
- [3] McClean PL, Gault VA, Irwin N, et al. Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP. *Diabetes Obes Metab*. 2008 Apr;10(4):336-42.
- [4] Cassidy RS, Irwin N, Platt PR. Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets. *Biol Chem*. 2008 Feb;389(2):189-93.
- [5] Neumann J, Hofmann B, Kirchhefer U, et al. Tirzepatide increased force of contraction in the isolated human atrium. *Naunyn Schmiedebergs Arch Pharmacol*. 2025 Oct;398(10):14451-14459.
- [6] Sparre-Ulrich AH, Hansen LS, Svendsen B, et al. Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. *Br J Pharmacol*. 2016 Jan;173(1):27-38.
- [7] McClean PL, Irwin N, Hunter K, et al. (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy. *Br J Pharmacol*. 2008 Nov;155(5):690-701.
- [8] Gault VA, O'Harte FP, Harriott P, et al. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. *Diabetologia*. 2003 Feb;46(2):222-30.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA